Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: A prospective observational cohort study

Archives of Internal Medicine

Volumn 156, Issue 14, 1996, Pages 1530-1536

  Singh, Gurkirpal ^a,c   Ramey, Dena Rosen ^a   Morfeld, Dianne ^a   Shi, Hong ^a   Hatoum, Hind T ^b   Fries, James F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; DRUG USE; FEMALE; GASTROINTESTINAL SYMPTOM; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SELF REPORT;

AGED; ANTACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; FEMALE; GASTROINTESTINAL DISEASES; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0030015717     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.14.1530     Document Type: Article

References (28)

1. O'Brien WM, Bagby GF. Rare adverse reactions to nonsteroidal anti-inflammatory drugs, I. J Rheumatol. 1985;12:13-20.
2. Metropolitan Life Insurance Co. Anti-arthritis medication usage: United States, 1991. Star Bull Metrop Insur Co. July-September 1992.
3. Butt JH, Barthel JS, Moore RA. Clinical spectrum of the upper gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Am J Med. 1988;84:5-14.
4. Fries JF, Williams CA, Bloch DA, Michel BA. NSAID-associated gastropathy: incidence and risk factor models. Am J Med. 1991;91:213-222.
5. Singh G, Ramey D, Morfeld D, Fries JF. Comparative toxicity of non-steroidal anti-inflammatory agents. Pharmacol Ther. 1994;62:175-191.
6. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med. 1991;115:787-796.
7. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114:257-263.
8. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA. Toward an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. Gastroenterology. 1989;96:647-655.
9. Gabriel SE, Campion ME, O'Fallon WM. A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 1994;37:333-341.
10. Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1989;149:2061-2065.
11. Edelson JT, Tosteson AN, Sax P. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA. 1990;264:41-47.
12. Jollis JG, Ancukiewicz M, DeLong ER, Pryor DB, Muhlbaier LH, Mark DB. Discordance of databases designed for claims payment versus clinical information systems. Ann Intern Med. 1993;119:844-850.
13. Fries JF, McShane DJ. ARAMIS (The American Rheumatism Association Medical Information System). West J Med. 1986;145:798-804.
14. Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease modifying antirheumatic drugs (DMARDs). Arthritis Rheum. 1993;36:297-306.
15. Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol. 1991;18:188-194.
16. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-145.
17. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, Disability and Pain scales. J Rheumatol. 1982;9:789-793.
18. Ramey DR, Raynauld JP, Fries JF. The Health Assessment Questionnaire 1992: status and review. Arthritis Care Res. 1992;5:119-129.
19. Fries JF, Spitz PW, Williams CA, Bloch DA, Singh G, Hubert HB. A toxicity index for comparison of side effects among different drugs. Arthritis Rheum. 1990;33:121-130.
20. Fries JF, Ramey DR, Singh G, Morfeld D, Bloch DA, Raynauld JP. A reevaluation of aspirin therapy in rheumatoid arthritis. Arch Intern Med. 1993;153:2465-2471.
21. Singh G, Williams CA, Ramey DR, Fries JF, A toxicity index for comparison of gastrointestinal toxicity of non-steroidal anti-inflammatory drugs (NSAIDs). Arthritis Rheum. 1993;36(suppl 9):S178.
22. Ehsanullah RS, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ. 1988;297:1017-1021.
23. Robinson MG, Griffin JW Jr, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs. Dig Dis Sci. 1989;34:424-428.
24. Oddsson E, Gudjonsson H, Thjodleifsson B. Comparison between ranitidine and omeprazole for protection against gastroduodenal damage caused by naproxen. Scand J Gastroenterol. 1992;27:1045-1048.
25. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol. Lancet. 1988;2:1277-1280.
26. Agrawal NM, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer: a randomized, controlled trial. Ann Intern Med. 1991;115:195-200.
27. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med. 1993;119:257-262.
28. Silverstein F, Graham D, Davies HW, Brittman RM, Struthers B, Geis GS. Reduction by misoprostol of clinically detected serious gastrointestinal complications associated with non-steroidal anti-inflammatory drug use in older patients with rheumatoid arthritis. Ann Intern Med. 1995;123:241-249.